Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) to Ring The Nasdaq Stock Market Closing Bell

What: Ritter Pharmaceuticals, Inc. (Nasdaq:RTTR), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, with an initial focus on developing potentially the first FDA approved prescription treatment for lactose intolerance, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Ira E. Ritter, Chairman, Co-Founder and Chief Strategic Officer, will ring the Closing Bell.

Where:Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:Monday, January 30, 2017 – 3:45 p.m. to 4:00 p.m. ET

Ritter Pharmaceuticals Contact:Ellen Mochizuki310-203-1000ellen@ritterpharma.com

Nasdaq MarketSite:Emily Pan(646) 441-5120emily.pan@nasdaq.com

Feed Information:Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK

Social Media:For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:http://nasdaq.tumblr.com/

Webcast: A live stream of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.

About Ritter PharmaceuticalsRitter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring functionality and discovering therapeutic potential gut microbiome changes may have on treating/preventing a variety of areas including: gastrointestinal diseases, immune-oncology, metabolic, and liver disease.

About NasdaqNasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of $10.0 trillion and approximately 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com

-NDAQA-

Ritter Pharmaceuticals (NASDAQ:RTTR)
過去株価チャート
から 6 2024 まで 7 2024